Geovax Labs Inc
GOVX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.97M
Close$
$0.79
56% downside
Current Fair Value
56% downsideOvervalued by 56% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.97 Million |
|---|---|
| Enterprise Value | $1.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.4 |
| Beta | 3.35 |
| Outstanding Shares | 2,008,134 |
Return
| Return on Equity | -4327.73% |
|---|---|
| Return on Assets | -716.50% |
| Return on Invested Capital | -3137.26% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | 10.83 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.05 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | 0.8 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 27, 2026
EPS Estimate
$-2.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 34.78%▲ 21.27% |
|---|---|
| Total Invested | $459,614▼ 2.50% |
| Investors Holding | 15▼ 4.00% |
ESG Score
No data
About Geovax Labs Inc
8 employees
CEO: David Dodd GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this pl...